Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache
Effect of Intranasal Oxytocin on Headache in Chronic Daily Headache
The objective of this prospective, randomized, double-blind, parallel-group,
 placebo-controlled study is to determine the effectiveness of intranasal oxytocin in subjects
 suffering from chronic daily headache. The primary outcome measure is the reduction in
 headache intensity after drug administration; secondary outcome measures are the headache
 symptoms, nausea, vomiting, photophobia, and phonophobia. Additional secondary outcome
 measures are intake of rescue medication and patient satisfaction over a period of 24 hours.
Inclusion Criteria:

 1. Headache on equal to or more than 15 days per month for at least 6 months; the
 headaches can be migraine or tension.

 2. More than half of the monthly headaches are of moderate or severe intensity on the
 4-point categorical pain rating scale and are assessed as 6 or higher on the 11-point
 numerical pain rating scale.

 3. Headaches typically last for at least 4 hours.

 4. Subjects are on a stable headache treatment, if any, for at least 2 months.

 Exclusion Criteria:

 1. Headache symptoms assessed to be predominately occipital.

 2. Allergy to oxytocin.

 3. History of addictive behavior (e.g. alcoholism, drug abuse).

 4. History of significant psychiatric disorder.

 5. History of clinically-significant, functionally-impairing cardiovascular or pulmonary
 disease.

 6. Upper-respiratory tract infection at the time of randomization.

 7. Past or current history of any condition that may hinder study procedures or confuse
 interpretation of data.

 8. Nasal obstruction of any cause as determined at screening.

 9. Major surgery or trauma within 4 weeks of screening.

 10. Women who are pregnant as evidenced by a serum HCG, nursing, or trying to conceive.

 11. Use of intranasally administered medications, for example, vasoconstrictors or
 corticosteroids, within 2 weeks of randomization.

 12. Use of an investigational medication or device within 30 days of randomization.

 13. Unable or unwilling to adhere to the study-specific procedures and restrictions.

 14. Any condition that in the opinion of the investigator would compromise the safety of
 the subject or the quality of the data.

 15. Alanine aminotransaminase (ALT) or aspartate aminotransaminase (AST) equal or greater
 than 3 times the upper limit of normal (ULN).

 16. Serum creatinine of equal or greater than 1.8 mg/dL. Resting, sitting systolic blood
 pressure equal or greater than 160 mmHg or diastolic blood pressure equal or greater
 than 100 mmHg at screening. For patients with previously diagnosed hypertension,
 antihypertensive medications must be stable for at least 30 days prior to screening.